[Contraception and endometriosis]

review public-domain-us
View on PubMed
AI-generated summary by claude@2026-06, 2026-06-09

Contraception choices for women with endometriosis vary based on severity and infertility, with specific hormonal contraceptives recommended for non-infertile severe cases and adenomyosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Contraception in women with endometriosis is unusual. In case of mild asymptomatic endometriosis all contraceptive methods may be used except predominant estrogenic action pills. In case of severe endometriosis if score is upon 70 or adhesion score upon 50 the patients are generally infertile. Contraception is not necessary. If scores are lower, medical treatment of endometriosis insure the contraception during the first six months. Afterwards an hydroxyprogesterone derivative pill such as cyproterone acetate, or a norpregnan derivative pill, or a combined estrogen progestogen pill, with predominant progestogen action (norgestrienon), or a monophasic pill containing norethisteron, or in case of metabolic diseases a pill containing gestoden, must be prescribed three out of four weeks. In case of adenomyosis, vaginal contraception is better. Perhaps in the next future, the new progestogen sterilant will be the best.

My notes (saved in your browser only)

Condition tags

endometriosisadenomyosis

MeSH descriptors

Contraception Endometriosis Uterine Neoplasms Contraception Contraindications Endometriosis Endometriosis Endometriosis Endometriosis Female Humans Infertility, Female Infertility, Female Severity of Illness Index Uterine Neoplasms Uterine Neoplasms Uterine Neoplasms Uterine Neoplasms

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-06-22T06:15:23.361955+00:00
pubmed
last seen: 2026-05-13T22:11:39.448046+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine